NICOLE STORLIE: Open Payments
NPI 1942573969 · VANCOUVER, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$778 in 22 payments from 11 companies in 2025. Trend: 2023 $687 · 2024 $538 · 2025 $778
Food & beverage: $778
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $181 |
| E.R. Squibb & Sons, L.L.C. | 3 | $149 |
| Supernus Pharmaceuticals, Inc. | 1 | $124 |
| Axsome Therapeutics, Inc. | 1 | $81 |
| Alkermes, Inc. | 2 | $60 |
| ABBVIE INC. | 2 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $26 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
Products named: INGREZZA, COBENFY, Qelbree, Auvelity, ARISTADA, VRAYLAR, REXULTI, CAPLYTA.
Industry payments across WA — which companies pay providers there.
